Protective effect on nephrotoxicity

  • Choung Se Young 

4.6.3. Conclusion

The objective of this study was to assess the effect and the mechanism of action of prokidin (a chromone compound found naturally as one of the ingredients of aloe) in terms of reducing cisplatin nephrotoxicity. The results indicated that prokidin was by far the most effective suppressant of cisplatin nephrotoxicity. The optimal cisplatin dosage was found to be 3 doses of 60mg/kg each and the optimal timing to be 72, 48 and 24 hours before cisplatin administration. The absence of any deleterious influence on cisplatin’s anti-cancer effect was also confirmed. The mechanism of nephrotoxicity suppression was by way of its effect on the neutrophil function of the renal blood. It stimulated the neutrophils to discharge oxygen radicals, thus preventing them from damaging organs. Based on these findings, we are of the view that prokidin has potential as a drug for reducing cisplatin-induced nephrotoxicity. However, successful efficacy trials with human subjects are required before it can be considered for clinical use.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alan MJ (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann. Int. Med., 101, 41–44Google Scholar
  2. 2.
    David DC, Daniel SL (1981) Anthony, A, Acute and chronic cisplatin nephropathy in rats. Lab Kid 44, 397–402Google Scholar
  3. 3.
    Dennis CD, Joseph L, Charlotte J, Jon K, Michael WW (1980) Mechanism of cis-platinum nephrotoxicity; II. Morphologic observations. J. Pharmacol. Exp Ther 213; 551–556Google Scholar
  4. 4.
    Dufour P, Bergerat JP, Eber M, Renayd P, Karcher V, Giron C, Leroy MJ Oberling F (1990) Cisplatin-induced acemia; A potential interference with iron metabolism at erythroid progenitors leved. 1; 49–54Google Scholar
  5. 5.
    Ellerby RA, Davis HL Jr, Ansfield FJ (1974) Phase I clinical trial of combined therapy with 5-FU (NSC-19893) and cis-platinum(II) diamminedichloride(NSC-119875). Cancer 34; 1005–1010PubMedCrossRefGoogle Scholar
  6. 6.
    Hook JB, McCormack M, Kluwe WM (1979) Biochemical mechanisms of nephrotoxicity. Rev. Biochem. Toxicol 1; 53–78Google Scholar
  7. 7.
    Hook JB, Hewitt WR (1986) Toxic responses of the kidney. In: Klaassen, C.D, Amdur, M.O. and Doull, J. (Eds.), Casarett and Doull’s Toxicology, The Basic Science of Poisons, 3rd Edn., MAcmillan New York 310–329Google Scholar
  8. 8.
    Jon DB, Julian BH (1981) Renal and electolyte disturbances associated with cisplatin Ann Int Med 95; 628–632Google Scholar
  9. 9.
    Jon DB, Julian BH (1981) Renal and electolyte disturbances associated with cisplatin Ann Int Med 95; 628–632Google Scholar
  10. 10.
    Juan CG, Daniel MH, Esteban C, Stephen SS (1977) The renal pathology in clinical trials of cis-platin ciamminedichloride Cancer 39; 1362–1371CrossRefGoogle Scholar
  11. 11.
    Kamalakar P, Wang JJ, Higby D (1976) Clinical Experience with cis-diamminedichloroplatinum(DDP) in chidren Proc Am Assoc Cancer Res Proc Am Soc Clin Oncol 17; 283Google Scholar
  12. 12.
    Kovach JS, Moertel CG, Schutt AJ (1973) Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel Cancer Chemother Rep 57; 357–359PubMedGoogle Scholar
  13. 13.
    Lippman AJ, Helson C, Helson L (1973) Clinical trials of cis-diamminedichloroplstinum (II)(NSC-119875). Cancer Chemother Rep 57; 191–200PubMedGoogle Scholar
  14. 14.
    Nicolas EM, John TH (1978) Platinum nephrotoxicity Am J Med 65; 307–314CrossRefGoogle Scholar
  15. 15.
    Piel IJ, Meyer D, Perlia CP (1974) Effects of cis-diamminedichloroplatinum(NSC-119875) on hearing function in man. Cancer Chemother Rep 58; 871–875PubMedGoogle Scholar
  16. 16.
    Robert S, Peter M, Joseph BG (1984) Uptake and metabolism of cisplatin by rat kidney Kid Int 25; 753–758Google Scholar
  17. 17.
    Robin SG, Gilbert HM (1983) The nephrotoxicity of cisplatin Life Sciences 32; 685–690CrossRefGoogle Scholar
  18. 18.
    Ronald CD, Bartlett RT, Robert CL, William AC (1973) Clinical and pharmacological studies with cis-diamminedichloroplatinum(NSC-119875). 33, 1310–1315Google Scholar
  19. 19.
    Rosenerg ML, Holoye PY, Johnson DE (1975) Bleomycin combination chemotherapy in the management of testicular neoplasia Cancer 36; 318–356CrossRefGoogle Scholar
  20. 20.
    Rush GF, Smith JH, Newton JF, Hook JB (1984) Chemically induced nephrotoxicity; role of metabolic activation. CRC crit Rev Toxicol 13; 99–160Google Scholar
  21. 21.
    Samuels ML, Holoye PY, Johnson DE (1975) Bleomycin combination chemotherapy in the management of testicular neoplasia Cancer 36; 318–356PubMedCrossRefGoogle Scholar
  22. 22.
    Sartori S, Nielsen I, Masotti M, Malacarne P (1991) Early and late hyperferremia during cisplatin chemotherapy J Chemo 3; 45–50Google Scholar
  23. 23.
    Walter GG, Brian DR (1984) Enzyme distribution along the nephron Kid Int 26; 101–111Google Scholar
  24. 24.
    Wittes RE, Brescia F, Young CW (1975) Combination chemotherapy with neck Oncology 32; 202–207PubMedCrossRefGoogle Scholar
  25. 25.
    Yagoda A, Watson RC, Whitmore WF (1977) Adriamycin in advanced urinary tract cancer; Experiene in 42 patients and review of the literature Cancer 39; 279–285Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Choung Se Young 
    • 1
  1. 1.College of PharmacyKyung Hee UniversitySeoulKorea

Personalised recommendations